Remdesivir Market 2028 By Dosage, Patient, Application, End user and Geography | The Insight Partners

report image

Remdesivir Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage (2.5mg, 5mg, 100mg, 200mg); Patient (Adult, Pediatric, Geriatric); Application (Ebola, SARS-COV, MERS-COV, COVID-19); End user (Hospitals, Clinics, Pharmacy and drug stores, Online pharmaceuticals.) and Geography

Report Code: TIPRE00017422 | No. of Pages: 150 | Category: Healthcare IT | Status: Upcoming

MARKET OVERVIEW

Remdesivir(RNA polymerase inhibitor) is a type of antiviral medicine developed by biopharmaceutical company Gilead Sciences. This drug is injected directly into the veins. This antiviral medication was approved by the US Food and Drug Administration in late October to treat patients with the coronavirus (COVID-19), making it the first drug to receive FDA approval for COVID-19 treatment. Remdesivir was given an emergency use authorization by the FDA.

MARKET SCOPE

The "Global Remdesivir Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the remdesivir market with detailed market segmentation by dosage, patient, application and end user. The report provides key statistics on the market status of the leading remdesivir market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on dosage the market is segmented as, 2.5 MG, 5MG, 100 MG and 200 MG.
  •   Based on patient the market is segmenetd as, adult, pediatric and geriatric.
  •   Based on application the market is segmented as, ebola, SARS-COV, MERS-COV, covid-19.
  •   Based on end user the market is segmenetd as, hospitals, clinics, pharmacy and drug stores, and online pharmaceuticals.

MARKET DYNAMICS
Drivers:

  •   Increasing prevalence Covid-19 and other viral disorders.
  •   Growing R&D efforts for developing novel therapies for such life threatening viral infections.
  •   High demand for remdesivir to treat Covid-19 infections.

Restraints:

  •   Whereas, presence of stringent regulatory framework, counterfeit medicines and high cost of remdesivir may restrict market growth during the forecast period.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The remdesivir market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the remdesivir market in these regions.

IMPACT OF COVID-19 ON REMDESIVIR MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the remdesivir market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from remdesivir market are anticipated to lucrative growth opportunities in the future with the rising demand for remdesivir in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the remdesivir market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Zydus Cadila
  •   Cipla Inc.
  •   Dr. Reddy's Laboratories Ltd
  •   Gilead Sciences, Inc.
  •   Hainan Haiyao
  •   Hetero
  •   Jubilant Pharma Limited
  •   Kelun Pharma
  •   Pfizer Inc.
  •   Mylan N.V (Viatris Inc.)
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

The List of Companies

1. Zydus Cadila
2. Cipla Inc.
3. Dr. Reddy's Laboratories Ltd
4. Gilead Sciences, Inc.
5. Hainan Haiyao
6. Hetero
7. Jubilant Pharma Limited
8. Kelun Pharma
9. Pfizer Inc.
10. Mylan N.V (Viatris Inc.)
TIPRE00017422
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




tip-analyst

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount